A Phase 1 interventional study of Ruzasvir in Hepatitis C Infection, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-12-24.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Hepatitis C by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Hepatitis C · Merck & Co., Inc.
Among the 92 studies in Hepatitis C by Merck & Co., Inc, this one is the 51st largest by enrollment of the 69 interventional ones that give a count, is one of 12 that started in 2014, is one of 28 in phase 1, and was the 68th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 92 studies in Hepatitis C by Merck & Co., Inc is open now. The open studies under Hepatitis C, anywhere →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 26 · Phase 3 13 · Phase 4 5
First in 1997; this study’s year is marked. 12 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 60 across the 69 interventional studies, 332 across the 23 observational. Of the 86 that completed or were terminated, 66 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 92 studies in Hepatitis C by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a 3-part study of Ruzasvir (MK-8408) for participants with hepatitis C infection. Successive participants will be enrolled as dose levels are evaluated to find the maximum safe and well tolerated dose of Ruzasvir. Part I will be for participants with hepatitis C virus (HCV) genotype 3 (GT3) and will run first: Part II will be for participants with HCV genotype 1a (GT1a), and Part III will be for participants with HCV genotype 2b (GT2b). Parts II and III may run concurrently. The primary study hypothesis is that a safe and tolerable dose of Ruzasvir that reduces viral load will be found to support further clinical investigation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
Drug: Ruzasvir
Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
Drug: Ruzasvir
Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
Drug: Ruzasvir
Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
Also known as: MK-8408
Maximum log10 HCV Ribonucleic Acid (RNA) Change From Baseline
Blood was collected at baseline and on Days 1, 2, 3, 4 and 5 to determine HCV RNA levels. Least squares means (LSM) and confidence intervals (CI) were obtained from an analysis of variance (ANOVA) model with maximum log10 HCV RNA change from baseline as response and a fixed effect for treatment. The primary hypothesis was that the mean change from baseline would be a reduction of ≥3 log10. A positive change from baseline indicates a reduction from baseline in log10 HCV RNA.
Time frame: Baseline and up to Day 5
Number of Participants Who Experienced One or More Adverse Events (AEs)
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
Time frame: Up to 61 days
Number of Participants Who Discontinued Study Drug Due To An AE
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
Time frame: Up to 5 days
Males or females of non-child bearing potential, with verified Hepatitis C virus (HCV) infection with genotype (GT) GT1a, GT2b or GT3 between the ages of 18 and 65 years (inclusive) were enrolled in this trial. In the GT1a group, one participant was later determined to be GT1b.
| Milestone | Ruzasvir 10 mg - GT3 | Ruzasvir 30 mg - GT3 | Ruzasvir 60 mg - GT3 | Ruzasvir 120 mg - GT3 | Ruzasvir 10 mg - GT2b | Ruzasvir 60 mg - GT2b | Ruzasvir 60 mg - GT1a |
|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 | 3 | 4 |
| Completed | 3 | 3 | 3 | 3 | 3 | 3 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Blood was collected at baseline and on Days 1, 2, 3, 4 and 5 to determine HCV RNA levels. Least squares means (LSM) and confidence intervals (CI) were obtained from an analysis of variance (ANOVA) model with maximum log10 HCV RNA change from baseline as response and a fixed effect for treatment. The primary hypothesis was that the mean change from baseline would be a reduction of ≥3 log10. A positive change from baseline indicates a reduction from baseline in log10 HCV RNA.
| log10 IU/mL | Ruzasvir 10 mg - GT3 | Ruzasvir 30 mg - GT3 | Ruzasvir 60 mg - GT3 | Ruzasvir 120 mg - GT3 | Ruzasvir 10 mg - GT2b | Ruzasvir 60 mg - GT2b | Ruzasvir 60 mg - GT1a | Ruzasvir 60 mg - GT1b |
|---|---|---|---|---|---|---|---|---|
| Maximum log10 HCV Ribonucleic Acid (RNA) Change From Baseline | 2.84 (1.94 to 3.74) | 3.03 (2.13 to 3.94) | 3.36 (2.46 to 4.26) | 1.81 (0.90 to 2.71) | 3.82 (3.15 to 4.50) | 3.62 (2.95 to 4.30) | 3.63 (2.46 to 4.81) | 3.82 (NA to NA) |
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
| Participants | Ruzasvir 10 mg - GT3 | Ruzasvir 30 mg - GT3 | Ruzasvir 60 mg - GT3 | Ruzasvir 120 mg - GT3 | Ruzasvir 10 mg - GT2b | Ruzasvir 60 mg - GT2b | Ruzasvir 60 mg - GT1a |
|---|---|---|---|---|---|---|---|
| Number of Participants Who Experienced One or More Adverse Events (AEs) | 0 | 0 | 2 | 1 | 2 | 2 | 2 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
| Participants | Ruzasvir 10 mg - GT3 | Ruzasvir 30 mg - GT3 | Ruzasvir 60 mg - GT3 | Ruzasvir 120 mg - GT3 | Ruzasvir 10 mg - GT2b | Ruzasvir 60 mg - GT2b | Ruzasvir 60 mg - GT1a |
|---|---|---|---|---|---|---|---|
| Number of Participants Who Discontinued Study Drug Due To An AE | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Up to 61 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruzasvir 10 mg - GT3 | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Ruzasvir 30 mg - GT3 | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Ruzasvir 60 mg - GT3 | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Ruzasvir 120 mg - GT3 | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Ruzasvir 10 mg - GT2b | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Ruzasvir 60 mg - GT2b | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Ruzasvir 60 mg - GT1a | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Event | Ruzasvir 10 mg - GT3 | Ruzasvir 30 mg - GT3 | Ruzasvir 60 mg - GT3 | Ruzasvir 120 mg - GT3 | Ruzasvir 10 mg - GT2b | Ruzasvir 60 mg - GT2b | Ruzasvir 60 mg - GT1a |
|---|---|---|---|---|---|---|---|
| Feeling hotGeneral disorders | 0/3 | 0/3 | 2/3 | 0/3 | 0/3 | 0/3 | 0/4 |
| Back painMusculoskeletal and connective tissue disorders | 0/3 | 0/3 | 2/3 | 0/3 | 0/3 | 0/3 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 | 0/4 |
| NauseaGastrointestinal disorders | 0/3 | 0/3 | 1/3 | 0/3 | 1/3 | 0/3 | 0/4 |
| Catheter site phlebitisGeneral disorders | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/3 | 0/4 |
| ContusionInjury, poisoning and procedural complications | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/4 |
| Procedural painInjury, poisoning and procedural complications | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/4 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/3 | 0/4 |
| HeadacheNervous system disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 1/4 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/3 | 0/4 |
| Age, Continuous(Years) | Ruzasvir 10 mg - GT3 | Ruzasvir 30 mg - GT3 | Ruzasvir 60 mg - GT3 | Ruzasvir 120 mg - GT3 | Ruzasvir 10 mg - GT2b | Ruzasvir 60 mg - GT2b | Ruzasvir 60 mg - GT1a | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 40.7 ± 6.5 | 36.0 ± 3.5 | 38.0 ± 10.4 | 40.7 ± 13.6 | 56.3 ± 2.1 | 54.0 ± 6.2 | 48.5 ± 6.2 | 45.0 ± 9.9 |
| Sex: Female, Male(Participants) | Ruzasvir 10 mg - GT3 | Ruzasvir 30 mg - GT3 | Ruzasvir 60 mg - GT3 | Ruzasvir 120 mg - GT3 | Ruzasvir 10 mg - GT2b | Ruzasvir 60 mg - GT2b | Ruzasvir 60 mg - GT1a | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 3 |
| Male | 2 | 3 | 3 | 3 | 2 | 2 | 4 | 19 |
No study locations are listed for this record.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
No publications or documents are linked to this record.
Ran from Mar 2014 to primary completion in Nov 2015, 19 months.
Results were first posted in Nov 2018, 3 years after primary completion.
Of 28 industry-sponsored phase 1 interventional studies under Hepatitis C, half reached primary completion within 6 months of starting (the median); a quarter within 4 and three quarters within 11. This study's 19 months is above that.
Counting every sponsor, half of 45 studies reached it within 9 months; a quarter within 4 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruzasvir